A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002490:Central Nervous System / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003498:Cyclic P-Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005021:Ethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009461:Neurologic Manifestations; D010078:Oxazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D001743:Urinary Bladder / Q000187:drug effects
D000970:Antineoplastic Agents; D003498:Cyclic P-Oxides; D005021:Ethylamines; D007166:Immunosuppressive Agents; D010078:Oxazines; D003520:Cyclophosphamide